Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
loteprednol etabonate + moxifloxacin
- Development stage
- Unknown
- Lead developer
- Optho Pharma
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Lotemox is a topical ophthalmic combination of loteprednol etabonate, a corticosteroid, and moxifloxacin, a broad-spectrum fluoroquinolone antibiotic. Developed by Optho Pharma, it is indicated for the treatment of steroid-responsive inflammatory ocular conditions where a superficial bacterial ocular infection or a risk of bacterial ocular infection exists, such as post-operative inflammation following ocular surgery. Loteprednol etabonate acts as an anti-inflammatory agent by binding to the glucocorticoid receptor and inhibiting the inflammatory response, while moxifloxacin acts as an antibacterial agent by inhibiting bacterial DNA gyrase and topoisomerase IV, thereby preventing bacterial DNA replication and transcription.
- Brand names
- Lotemox
- Other names
- loteprednol + moxifloxacinloteprednol etabonate + moxifloxacinloteprednol etabonate and moxifloxacinmoxifloxacin + loteprednolmoxifloxacin + loteprednol etabonatemoxifloxacin and loteprednol etabonate
02
Targets
DNA gyraseTopo IV (Bacterial Topoisomerase IV)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on loteprednol etabonate + moxifloxacin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on loteprednol etabonate + moxifloxacin.